Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer.

ABSTRACT: Prostate cancer (PCa) is the most commonly diagnosed cancer and the second most common cause of death due to cancer. About 30% of patients with PCa who have been castrated develop a castration-resistant form of the disease (CRPC), which is incurable. In the last decade, new treatments that control the disease have emerged, slowing progression and spread and prolonging survival while maintaining the quality of life. These include immunotherapies; however, we do not yet know the optimal combination and sequence of these therapies with the standard ones. All therapies are not always suitable for every patient due to co-morbidities or adverse effects of therapies or both, so there is an urgent need for further work on new therapeutic options. Advances in cancer immunotherapy with an immune che

SUBMITTER: Hawlina S 

PROVIDER: S-EPMC10382052 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature